Since recent validation of the EULAR definition of arthralgia in progression to RA indicated a need to combine clinical symptoms with biomarkers (18), we studied which of the clinical joint symptoms discriminated for the presence of RA-specific antibodies, RF and ACPA, elevated CRP, and survivin. This evidence concerns the gene CRP and rheumatoid arthritis.